David W Smith

Title: The Innovations of David W. Smith

Introduction

David W. Smith is a notable inventor based in Harlow, GB. He has made significant contributions to the field of biotechnology, particularly in the development of transgenic models for studying human diseases. His work has implications for understanding and potentially treating conditions related to amyloid precursor proteins.

Latest Patents

David W. Smith holds a patent for a transgenic mouse expressing a familial form of human amyloid precursor protein. This innovative model involves transgenic non-human mammals that express a nucleic acid construct comprising a DNA sequence encoding a human amyloid precursor protein FAD variant. Specifically, at amino acid position 717, valine is substituted by isoleucine. These transgenic mice serve as assay systems for determining compounds that can effectively modulate the production of human amyloid precursor protein in the brain and isolated neuronal cells. The mice have been shown to produce the APP-FAD variant in their brains, as demonstrated by mRNA and protein assays.

Career Highlights

David W. Smith is currently employed at Merck & Company, Inc., where he continues to advance research in the field of biotechnology. His work focuses on creating innovative models that can aid in the understanding of neurodegenerative diseases. With a patent portfolio that includes a significant innovation, he has established himself as a key figure in his area of expertise.

Collaborations

Throughout his career, David has collaborated with notable colleagues, including Gurparlash Singh and Howard Y. Chen. These collaborations have contributed to the advancement of research and development in the field of transgenic models.

Conclusion

David W. Smith's contributions to biotechnology, particularly through his patent on transgenic mice, highlight the importance of innovative research in understanding human diseases. His work at Merck & Company, Inc. continues to pave the way for future advancements in the field.